At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 280 target
Drug / intervention
AD-209 +3 moredrug
Likely dose
Not stated in record
Key inclusion· 1
- ✓Signed informed consent
Key exclusion· 1
- ✕Orthostatic hypotension with symptoms
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06348576Phase 3RecruitingUpdate OverdueUpdated 25mo ago · Completion was 16mo agoEnrollment Stalled
Update Overdue
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating AD-209, AD-2091, and 2 other interventions for Hypertension,Essential. Currently recruiting, targeting 280 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of AD-209
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension,Essential
CountriesSouth Korea
Collaborators--
Timeline
Phase 3RecruitingOverdue
20252026
First PostedApr 2024
Enrollment StartMay 2024
Primary CompletionFeb 2025
TodayJul 2026
First PostedApr 4, 2024
Enrollment StartMay 20, 2024
Primary CompletionFeb 1, 2025
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.2 years ago
Interventions
AD-209drug
PO, Once daily(QD), 8weeks
AD-2091drug
PO, Once daily(QD), 8weeks
AD-209 Placebodrug
PO, Once daily(QD), 8weeks
AD-2091 Placebodrug
PO, Once daily(QD), 8weeks